UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.45% | 8.00% | 10.85% | 8.98% | 9.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.45% | 8.00% | 10.85% | 8.98% | 9.29% |
| Cost of Revenue | 40.15% | 33.73% | 25.48% | 7.47% | -5.13% |
| Gross Profit | 19.41% | 5.23% | 9.21% | 9.15% | 11.13% |
| SG&A Expenses | 26.86% | 36.86% | 38.01% | 35.20% | 31.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.63% | 33.46% | 32.91% | 30.87% | 27.00% |
| Operating Income | -27.56% | -60.64% | -56.44% | -57.52% | -49.36% |
| Income Before Tax | -23.68% | -45.18% | -37.55% | -34.77% | -26.16% |
| Income Tax Expenses | -97.25% | -25.64% | 5.33% | -19.81% | -27.76% |
| Earnings from Continuing Operations | -20.98% | -42.70% | -36.43% | -32.70% | -24.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.98% | -42.70% | -36.43% | -32.70% | -24.09% |
| EBIT | -27.56% | -60.64% | -56.44% | -57.52% | -49.36% |
| EBITDA | -26.75% | -60.06% | -57.20% | -58.75% | -50.70% |
| EPS Basic | -6.68% | -18.50% | -5.87% | 7.40% | 19.44% |
| Normalized Basic EPS | -7.96% | -21.73% | -7.56% | 5.58% | 18.03% |
| EPS Diluted | -6.68% | -18.50% | -5.87% | 7.40% | 19.44% |
| Normalized Diluted EPS | -7.96% | -21.73% | -7.56% | 5.58% | 18.03% |
| Average Basic Shares Outstanding | 12.30% | 18.54% | 29.42% | 40.91% | 48.77% |
| Average Diluted Shares Outstanding | 12.30% | 18.54% | 29.42% | 40.91% | 48.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |